Small Pharma Inc. (DMTTF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in London, United Kingdom. The current CEO is George Tziras.
DMTTF has IPO date of 2021-06-07, listed on the Other OTC, a market capitalization of $37.51M.
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.
